Amunix Pharmaceuticals snaps up $117m Series B

Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this